-+ 0.00%
-+ 0.00%
-+ 0.00%

Zealand Pharma starts Phase 2 trial of petrelintide-enicepatide combination for obesity

PUBT·11/18/2026 06:01:42
Listen to the news
Zealand Pharma starts Phase 2 trial of petrelintide-enicepatide combination for obesity
  • Zealand Pharma initiated the Phase 2 ZYNERGY trial of petrelintide with enicepatide in people with obesity or overweight with weight-related comorbidities.
  • The study tests three once-weekly combination dosing regimens over 40 weeks against placebo or either drug alone.
  • The trial will assess weight loss, safety and tolerability; results are pending.
  • The combination aims to improve weight loss and cardiometabolic risk markers while maintaining tolerability, supporting an amylin-based weight-management franchise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180100PRIMZONEFULLFEED1001304194) on November 18, 2026, and is solely responsible for the information contained therein.